Possible involvement of muscarinic receptors in psychiatric disorders: A focus on schizophrenia and mood disorders

Current Molecular Medicine

Volumn 15, Issue 3, 2015, Pages 253-264

  Dean, B ^a,b   Scarr, E ^a,b  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Acetylcholine; Bipolar disorders; Major depressive disorders; Muscarinic receptor; Neuroinflammation; Schizophrenia

Indexed keywords

ARECOLINE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR; POTASSIUM CHANNEL; SCOPOLAMINE; XANOMELINE;

ARTICLE; AUDITORY CORTEX; AUTOPSY; BRAIN NERVE CELL; CELL PROLIFERATION; CHOLINERGIC SYSTEM; CONVULSIVE THERAPY; DEPRESSION; DRUG TARGETING; HUMAN; HYPERPOLARIZATION; HYPOXIA; MEMORY; MOLECULAR PATHOLOGY; MOOD DISORDER; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NONHUMAN; PREPULSE INHIBITION; PROTEIN EXPRESSION; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA; VISUAL CORTEX; ANIMAL; BRAIN; METABOLISM; PATHOLOGY; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ANIMALS; BRAIN; DEPRESSION; HUMANS; MOOD DISORDERS; RECEPTORS, MUSCARINIC; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 84929628133     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524015666150330144821     Document Type: Article

References (151)

1. [1] Scarr E, Dean B. Role of the cholinergic system in the pathology and treatment of schizophrenia. Exp Rev Neurotherapeut 2009; 9: 73-86.
2. [2] Janowsky DS, el-Yousef MK, Davis JM, Sekerke HJ. A cholinergic-adrenergic hypothesis of mania and depression. Lancet 1972; 2: 632-635.
3. [3] Whitteridge D. The role of acetylcholine in synaptic transmission; a critical review. J Neurol Neurosurg Psychiatry 1948; 11: 134-140.
4. [4] Money TT, Scarr E, Udawela M, et al. Treating schizophrenia: novel targets for the cholinergic system. CNS Neurol Disord Drug Targets 2010; 9: 241-256.
5. [5] Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 2009; 89: 73-120.
6. [6] Gray JA, Roth BL. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull 2007; 33: 1100-1119.
7. [7] Romanelli MN, Gratteri P, Guandalini L, et al. Central Nicotinic Receptors: Structure, Function, Ligands, and Therapeutic Potential. Chem Med Chem 2007; 2: 746-767.
8. [8] Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998; 50: 279-290.
9. [9] Thiele A. Muscarinic signaling in the brain. Annu Rev Neurosci 2013; 36: 271-294.
10. [10] Raedler TJ, Bymaster FP, Tandon R, Copolov D, Dean B. Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry 2007; 12: 232-246.
11. [11] Haga K, Kruse AC, Asada H, et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 2012; 482: 547-551.
12. [12] Kruse AC, Hu J, Pan AC, et al. Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 2012; 482: 552-556.
13. [13] Conn PJ, Jones CK, Lindsley CW. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci 2009; 30: 148-155.
14. [14] Scarr E, Dean B. Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia? J Neurochem 2008; 107: 1188-1195.
15. [15] Dean B, Crook JM, Opeskin K, et al. The density of muscarinic M1 receptors is decreased in the caudateputamen of subjects with schizophrenia. Mol Psychiatry 1996; 1: 54-58.
16. [16] Crook JM, Dean B, Pavey G, Copolov D. The binding of [3H] AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. Life Sci 1999; 64: 1761-1771.
17. [17] Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 2001; 158: 918-925.
18. [18] Deng C, Huang XF. Decreased density of muscarinic receptors in the superior temporal gyrus in schizophrenia. J Neurosci Res 2005; 81: 883-890.
19. [19] Zavitsanou K, Katsifis A, Filomena M, Xu-Feng H. Investigation of M1/M4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 2004; 29: 619-625.
20. [20] Mancama D, Arranz MJ, Landau S, Kerwin R. Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003; 119: 2-6.
21. [21] Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E. Decreased muscarinic(1) receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 2002; 7: 1083-1091.
22. [22] Scarr E, Sundram S, Keriakous D, Dean B. Altered hippocampal muscarinic m4, but not m1, receptor expression from subjects with schizophrenia. Biol Psychiatry 2007; 61: 1161-1170.
23. [23] Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 2000; 48: 381-388.
24. [24] Dean B, Gray L, Keriakous D, Scarr E. A comparison of M1 and M4 muscarinic receptors in the thalamus from control subjects and subjects with schizophrenia. Thalamus & Related Systems 2004; 2: 287-295.
25. [25] Raedler TJ, Knable MB, Jones DW, et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 2003; 160: 118-127.
26. [26] Felder CC. Muscarinic acetylcholine receptors: signal transduction through multiple effectors. FASEB J 1995; 9: 619-625.
27. [27] Zavitsanou K, Katsifis A, Yu Y, Huang XF. M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain Res Bull 2005; 65: 397-403.
28. [28] Scarr E, Keriakous D, Crossland N, Dean B. No change in cortical muscarinic M2, M3 receptors or [35S] GTPgammaS binding in schizophrenia. Life Sci 2006; 78: 1231-1237.
29. [29] Dean B, Crook JM, Pavey G, Opeskin K, Copolov DL. Muscarinic1 and 2 receptor mRNA in the human caudateputamen: no change in m1 mRNA in schizophrenia. Mol Psychiatry 2000; 5: 203-207.
30. [30] Tamminga CA. Accelerating new knowledge in schizophrenia. Am J Psychiatry 2008; 165: 949-951.
31. [31] Scarr E, Cowie TF, Kanellakis S, et al. Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry 2009; 14: 1017-1023.
32. [32] Gibbons AS, Scarr E, Boer S, et al. Widespread decreases in cortical muscarinic receptors in a subset of people with schizophrenia. Int J Neuropsychopharmacol 2013; 16: 37-46.
33. [33] Salah-Uddin H, Scarr E, Pavey G, et al. Altered M(1) muscarinic acetylcholine receptor (CHRM1)-Galpha(q/11) coupling in a schizophrenia endophenotype. Neuropsychopharmacology 2009; 34: 2156-2166.
34. [34] Scarr E, Craig JM, Cairns MJ, et al. Decreased cortical muscarinic M1 receptors in schizophrenia are associated with changes in gene promoter methylation, mRNA and gene targeting microRNA. Transl Psychiatry 2013; 3: e230.
35. [35] Cannon DM, Carson RE, Nugent AC, et al. Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry 2006; 63: 741-747.
36. [36] Cannon DM, Klaver JK, Gandhi SK, et al. Genetic variation in cholinergic muscarinic-2 receptor gene modulates M(2) receptor binding in vivo and accounts for reduced binding in bipolar disorder. Mol Psychiatry 2011; 16: 407-418.
37. [37] Gibbons AS, Scarr E, McLean C, Sundram S, Dean B. Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. J Affect Disord 2009; 116: 184-191.
38. [38] Jeon W-J, Gibbons AS, Dean B. The use of a modified [3H] 4-DAMP radioligand binding assay with increased selectivity for [59] muscarinic M3 receptor shows that cortical CHRM3 levels are not altered in mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 2013; 47: 7-12.
39. [39] Tsuang M. Schizophrenia: genes and environment. Biol Psychiatry 2000; 47: 210-220.
40. [40] Craddock N, Forty L. Genetics of affective (mood) disorders. Eur J Hum Genet 2006; 14: 660-668.
41. [41] Rapoport JL, Addington AM, Frangou S, Psych MR. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 2005; 10: 434-449.
42. [42] Bale TL, Baram TZ, Brown AS, et al. Early life programming and neurodevelopmental disorders. Biol Psychiatry 2010; 68: 314-319.
43. [43] Clancy B, Finlay BL, Darlington RB, Anand KJ. Extrapolating brain development from experimental species to humans. Neurotoxicology 2007; 28: 931-937.
44. [44] Anju TR, Smijin S, Chinthu R, Paulose CS. Decreased cholinergic function in the cerebral cortex of hypoxic neonatal rats: role of glucose, oxygen and epinephrine resuscitation. Respir Physiol Neurobiol 2012; 180: 8-13.
45. [45] Benninghoff J, Rauh W, Brantl V, et al. Cholinergic impact on neuroplasticity drives muscarinic M1 receptor mediated differentiation into neurons. World J Biol Psychiatry 2013; 14: 241-246.
46. [46] De Angelis F, Bernardo A, Magnaghi V, Minghetti L, Tata AM. Muscarinic receptor subtypes as potential targets to modulate oligodendrocyte progenitor survival, proliferation, and differentiation. Dev Neurobiol 2012; 72: 713-728.
47. [47] Zhang Y, Hamilton SE, Nathanson NM, Yan J. Decreased input-specific plasticity of the auditory cortex in mice lacking M1 muscarinic acetylcholine receptors. Cereb Cortex 2006; 16: 1258-1265.
48. [48] Zhang Y, Dyck RH, Hamilton SE, Nathanson NM, Yan J. Disrupted tonotopy of the auditory cortex in mice lacking M1 muscarinic acetylcholine receptor. Hear Res 2005; 201: 145-155.
49. [49] Origlia N, Kuczewski N, Aztiria E, et al. Muscarinic acetylcholine receptor knockout mice show distinct synaptic plasticity impairments in the visual cortex. J Physiol 2006; 577: 829-840.
50. [50] Silbersweig DA, Stern E, Frith C, et al. A functional neuroanatomy of hallucinations in schizophrenia. Nature 1995; 378: 176-179.
51. [51] Bartko SJ, Romberg C, White B, et al. Intact attentional processing but abnormal responding in M1 muscarinic receptor-deficient mice using an automated touchscreen method. Neuropharmacology 2011; 61: 1366-1378.
52. [52] Huron C, Danion JM, Giacomoni F, et al. Impairment of recognition memory with, but not without, conscious recollection in schizophrenia. Am J Psychiatry 1995; 152: 1737-1742.
53. [53] Uslaner JM, Eddins D, Puri V, et al. The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque. Psychophamacology (Berlin) 2013; 225: 21-30.
54. [54] Liao DL, Hong CJ, Chen HM, et al. Association of muscarinic m1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients. Neuropsychobiology 2003; 48: 72-76.
55. [55] Scarr E, Sundram S, Deljo A, et al. Muscarinic M1 receptor sequence: preliminary studies on its effects on cognition and expression. Schizophr Res 2012; 138: 94-98.
56. [56] Ragozzino ME, Jih J, Tzavos A. Involvement of the dorsomedial striatum in behavioral flexibility: role of muscarinic cholinergic receptors. Brain Res 2002; 953: 205-214.
57. [57] Goff DC, Hill M, Barch D. The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav 2011; 99: 245-253.
58. [58] Nathan PJ, Watson J, Lund J, et al. The potent M(1) receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. Int J Neuropsychopharmacol 2013; 16: 721-731.
59. [59] Greely H, Sahakian B, Harris J, et al. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 2008; 456: 702-705.
60. [60] Farah MJ, Illes J, Cook-Deegan R, et al. Neurocognitive enhancement: what can we do and what should we do? Nat Rev Neurosci 2004; 5: 421-425.
61. [61] Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther 2008; 117: 232-243.
62. [62] Ito Y, Oyunzul L, Seki M, et al. Quantitative analysis of the loss of muscarinic receptors in various peripheral tissues in M1-M5 receptor single knockout mice. Br J Pharmacol 2009; 156: 1147-1153.
63. [63] Jiang S, Wang Y, Ma Q, et al. M1 muscarinic acetylcholine receptor interacts with BACE1 and regulates its proteosomal degradation. Neurosci Lett 2012; 515: 125-130.
64. [64] Janickova H, Rudajev V, Zimcik P, et al. Uncoupling of M1 muscarinic receptor/G-protein interaction by amyloid beta(1-42). Neuropharmacology 2013; 67: 272-283.
65. [65] Caccamo A, Oddo S, Billings LM, et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 2006; 49: 671-682.
66. [66] Religa D, Laudon H, Styczynska M, et al. Amyloid beta pathology in Alzheimer's disease and schizophrenia. Am J Psychiatry 2003; 160: 867-872.
67. [67] Frisoni GB, Prestia A, Geroldi C, et al. Alzheimer's CSF markers in older schizophrenia patients. Int J Geriatr Psychiatry 2011; 26: 640-648.
68. [68] Wu W, Saunders RC, Mishkin M, Turchi J. Differential effects of m1 and m2 receptor antagonists in perirhinal cortex on visual recognition memory in monkeys. Neurobiol Learn Mem 2012; 98: 41-46.
69. [69] O'Donnell BF, Swearer JM, Smith LT, et al. Selective deficits in visual perception and recognition in schizophrenia. Am J Psychiatry 1996; 153: 687-692.
70. [70] Tang Y, Mishkin M, Aigner TG. Effects of muscarinic blockade in perirhinal cortex during visual recognition. Proc Natl Acad Sci U S A 1997; 94: 12667-12669.
71. [71] Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007; 32: 1888-1902.
72. [72] Bell LA, Bell KA, McQuiston AR. Synaptic muscarinic response types in hippocampal CA1 interneurons depend on different levels of presynaptic activity and different muscarinic receptor subtypes. Neuropharmacology 2013; 73C: 160-173.
73. [73] Shirey JK, Xiang Z, Orton D, et al. An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat Chem Biol 2008; 4: 42-50.
74. [74] Deicken RF, Zhou L, Schuff N, Fein G, Weiner MW. Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy. Biol Psychiatry 1998; 43: 483-488.
75. [75] Peterfi Z, Urban GM, Papp OI, et al. Endocannabinoidmediated long-term depression of afferent excitatory synapses in hippocampal pyramidal cells and GABAergic interneurons. J Neurosci 2012; 32: 14448-14463.
76. [76] Edwards JG, Gibson HE, Jensen T, et al. A novel non-CB1/TRPV1 endocannabinoid-mediated mechanism depresses excitatory synapses on hippocampal CA1 interneurons. Hippocampus 2012; 22: 209-221.
77. [77] Arnold JC, Boucher AA, Karl T. The yin and yang of cannabis-induced psychosis: the actions of Delta(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia. Curr Pharm Des 2012; 18: 5113-5130.
78. [78] Kim J, Isokawa M, Ledent C, Alger BE. Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus. J Neurosci 2002; 22: 10182-10191.
79. [79] Ohno-Shosaku T, Matsui M, Fukudome Y, et al. Postsynaptic M1 and M3 receptors are responsible for the muscarinic enhancement of retrograde endocannabinoid signalling in the hippocampus. Eur J Neurosci 2003; 18: 109-116.
80. [80] Tzavara ET, Bymaster FP, Felder CC, et al. Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. Mol Psychiatry 2003; 8: 673-679.
81. [81] Volpicelli LA, Levey AI. Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog Brain Res 2004; 145: 59-66.
82. [82] Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001; 22: 565-572.
83. [83] Scarr E, Gibbons AS, Neo J, Udawela M, Dean B. Cholinergic connectivity: it's implications for psychiatric disorders. Front Cell Neurosci 2013; 7: 55.
84. [84] Katona I, Sperlagh B, Sik A, et al. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 1999; 19: 4544-4558.
85. [85] Benes FM, Khan Y, Vincent SL, Wickramasinghe R. Differences in the subregional and cellular distribution of GABAA receptor binding in the hippocampal formation of schizophrenic brain. Synapse 1996; 22: 338-349.
86. [86] Dean B, Moller HJ, Svensson TH, et al. Problems and Solutions to Filling the Drying Drug Pipeline for Psychiatric Disorders: A Report from the Inaugural 2012 CINP Think-Tank. Int J Neuropsychopharmacol 2014; 17: 137-148.
87. [87] Young JW, Zhou X, Geyer MA. Animal models of schizophrenia. Curr Top Behav Neurosci 2010; 4: 391-433.
88. [88] Veeraragavan S, Graham D, Bui N, et al. Genetic reduction of muscarinic M4 receptor modulates analgesic response and acoustic startle response in a mouse model of fragile X syndrome (FXS). Behav Brain Res 2012; 228: 1-8.
89. [89] Felder CC, Porter AC, Skillman TL, et al. Elucidating the role of muscarinic receptors in psychosis. Life Sci 2001; 68: 2605-2613.
90. [90] Koshimizu H, Leiter LM, Miyakawa T. M4 muscarinic receptor knockout mice display abnormal social behavior and decreased prepulse inhibition. Mol Brain 2012; 5: 10.
91. [91] Jones CK, Shannon HE. Muscarinic cholinergic modulation of prepulse inhibition of the acoustic startle reflex. J Pharmacol Exp Ther 2000; 294: 1017-1023.
92. [92] Lipska BK, Swerdlow NR, Geyer MA, et al. Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychophamacology (Berlin) 1995; 122: 35-43.
93. [93] Hauser J, Rudolph U, Keist R, et al. Hippocampal alpha5 subunit-containing GABAA receptors modulate the expression of prepulse inhibition. Mol Psychiatry 2005; 10: 201-207.
94. [94] Carlsson A. Does dopamine play a role in schizophrenia? Psychol Med 1977; 7: 583-597.
95. [95] Tzavara ET, Bymaster FP, Davis RJ, et al. M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. FASEB J 2004; 18: 1410-1412.
96. [96] Flagstad P, Mork A, Glenthoj BY, et al. Disruption of neurogenesis on gestational day 17 in the rat causes behavioral changes relevant to positive and negative schizophrenia symptoms and alters amphetamine-induced dopamine release in nucleus accumbens. Neuropsychopharmacology 2004; 29: 2052-2064.
97. [97] Bird ED, Spokes EG, Iversen LL. Increased dopamine concentration in limbic areas of brain from patients dying with schizophrenia. Brain 1979; 102: 347-360.
98. [98] Dean B. Signal transmission, rather than reception, is the underlying neurochemical abnormality in schizophrenia. Aust N Z J Psychiatry 2000; 34: 560-569.
99. [99] Dean B. Neurochemistry of schizophrenia and psychosis: the contribution of neuroimaging. Curr Top Med Chem 2013; 12: 2375-2392.
100. [100] Turner J, Hughes LF, Toth LA. Sleep, activity, temperature and arousal responses of mice deficient for muscarinic receptor M2 or M4. Life Sci 2010; 86: 158-169.
101. [101] Gannon RL, Millan MJ. LY2033298, a positive allosteric modulator at muscarinic M(4) receptors, enhances inhibition by oxotremorine of light-induced phase shifts in hamster circadian activity rhythms. Psychophamacology (Berlin) 2012; 224: 231-240.
102. [102] Guzman MS, De Jaeger X, Drangova M, Prado MA, Gros R, Prado VF. Mice with selective elimination of striatal acetylcholine release are lean, show altered energy homeostasis and changed sleep/wake cycle. J Neurochem 2013; 124: 658-669.
103. [103] Lazarus M, Huang ZL, Lu J, Urade Y, Chen JF. How do the basal ganglia regulate sleep-wake behavior? Trends Neurosci 2012; 35: 723-732.
104. [104] Pritchett D, Wulff K, Oliver PL, et al. Evaluating the links between schizophrenia and sleep and circadian rhythm disruption. J Neural Transm 2012; 119: 1061-1075.
105. [105] Iannazzo L, Majewski H. M(2)/M(4)-muscarinic receptors mediate automodulation of acetylcholine outflow from mouse cortex. Neurosci Lett 2000; 287: 129-132.
106. [106] Douglas CL, Baghdoyan HA, Lydic R. M2 muscarinic autoreceptors modulate acetylcholine release in prefrontal cortex of C57BL/6J mouse. J Pharmacol Exp Ther 2001; 299: 960-966.
107. [107] Bymaster FP, McKinzie DL, Felder CC, Wess J. Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem Res 2003; 28: 437-442.
108. [108] Arrighi N, Bodei S, Lucente A, et al. Muscarinic receptors stimulate cell proliferation in the human urothelium-derived cell line UROtsa. Pharmacol Res 2011; 64: 420-425.
109. [109] Ferretti M, Fabbiano C, Di BM, et al. M2 muscarinic receptors inhibit cell proliferation in human glioblastoma cell lines. Life Sci 2012; 91: 1134-1137.
110. [110] Ferretti M, Fabbiano C, Di BM, et al. M2 receptor activation inhibits cell cycle progression and survival in human glioblastoma cells. J Cell Mol Med 2013; 17: 552-566.
111. [111] Reif A, Fritzen S, Finger M, et al. Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol Psychiatry 2006; 11: 514-522.
112. [112] Lau JY, Eley TC. The genetics of mood disorders. Annu Rev Clin Psychol 2010; 6: 313-337.
113. [113] Medalla M, Barbas H. The anterior cingulate cortex may enhance inhibition of lateral prefrontal cortex via m2 cholinergic receptors at dual synaptic sites. J Neurosci 2012; 32: 15611-15625.
114. [114] Koenigs M, Grafman J. The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex. Behav Brain Res 2009; 201: 239-243.
115. [115] Konarski JZ, McIntyre RS, Kennedy SH, et al. Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. Bipolar Disord 2008; 10: 1-37.
116. [116] Mansouri FA, Tanaka K, Buckley MJ. Conflict-induced behavioural adjustment: a clue to the executive functions of the prefrontal cortex. Nat Rev Neurosci 2009; 10: 141-152.
117. [117] Janowsky DS, el-Yousef MK, Davis JM. Acetylcholine and depression. Psychosom Med 1974; 36: 248-257.
118. [118] Millan MJ, Agid Y, Brune M, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov 2012; 11: 141-168.
119. [119] Wang L, Yuan LL. Activation of M2 muscarinic receptors leads to sustained suppression of hippocampal transmission in the medial prefrontal cortex. J Physiol 2009; 587: 5139-5147.
120. [120] Dean B. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. Int J Neuropsychopharmacol 2011; 14: 997-1012.
121. [121] Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35: 804-817.
122. [122] Jacoby DB, Xiao HQ, Lee NH, Chan-Li Y, Fryer AD. Virusand interferon-induced loss of inhibitory M2 muscarinic receptor function and gene expression in cultured airway parasympathetic neurons. J Clin Invest 1998; 102: 242-248.
123. [123] Jacoby DB, Yost BL, Kumaravel B, et al. Glucocorticoid treatment increases inhibitory m(2) muscarinic receptor expression and function in the airways. Am J Respir Cell Mol Biol 2001; 24: 485-491.
124. [124] Nie Z, Scott GD, Weis PD, et al. Role of TNF-alpha in virusinduced airway hyperresponsiveness and neuronal M(2) muscarinic receptor dysfunction. Br J Pharmacol 2011; 164: 444-452.
125. [125] Proskocil BJ, Bruun DA, Jacoby DB, et al. Macrophage TNF-+¦ mediates parathion-induced airway hyperreactivity in guinea pigs. Am J Physiol Lung Cell Mol Physiol 2013; 304: L519-L529.
126. [126] Dean B, Tawadros N, Scarr E, Gibbons AS. Regionallyspecific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder. J Affect Disord 2010; 120: 245-248.
127. [127] Dean B, Boer S, Gibbons A, Money T, Scarr E. Recent advances in postmortem pathology and neurochemistry in schizophrenia. Curr Opin Psychiatry 2009; 22: 154-160.
128. [128] Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35.
129. [129] Tosi G, Bortot B, Ruozi B, et al. Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier. Curr Med Chem 2013; 20: 2212-2225.
130. [130] Cohen LH, Thale T, Tissenbaum MJ. Acetylcholine treatment of schizophrenia. Arch Neurol Psychiatr 1944; 51: 171-175.
131. [131] Forrer GR, Miller JJ. Atropine coma: a somatic therapy in psychiatry. Am J Psychiatry 1958; 115: 455-458.
132. [132] Neu C, DiMascio A, Demirgian E. Antiparkinson medication in the treatment of extrapyramidal side effects: single of multiple daily doses? Curr Ther Res Clin Exp 1972; 14: 246-251.
133. [133] Caradoc-Davies G, Menkes DB, Clarkson HO, Mullen PE. A study of the need for anticholinergic medication in patients treated with long-term antipsychotics. Aust N Z J Psychiatry 1986; 20: 225-232.
134. [134] Singh MM, Smith JM. Reversal of some therapeutic effects of an antipsychotic agent by an antiparkinsonism drug. J Nerv Ment Dis 1973; 157: 50-58.
135. [135] Baker LA, Cheng LY, Amara IB. The withdrawal of benztropine mesylate in chronic schizophrenic patients. Br J Psychiatry 1983; 143: 584-590.
136. [136] Bymaster FP, Felder C, Ahmed S, McKinzie D. Muscarinic receptors as a target for drugs treating schizophrenia. Curr Drug Targets CNS Neurol Disord 2002; 1: 163-181.
137. [137] Dean B. M1 receptor agonism, a possible treatment for cognitive deficits in schizophrenia. Neuropsychopharmacology 2004; 29: 1583-1584.
138. [138] Sullivan RJ, Allen JS, Otto C, Tiobech J, Nero K. Effects of chewing betel nut (Areca catechu) on the symptoms of people with schizophrenia in Palau, Micronesia. Br J Psychiatry 2000; 177: 174-178.
139. [139] Sullivan RJ, Andres S, Otto C, Miles W, Kydd R. The effects of an indigenous muscarinic drug, Betel nut (Areca catechu), on the symptoms of schizophrenia: a longitudinal study in Palau, Micronesia. Am J Psychiatry 2007; 164: 670-673.
140. [140] Odagaki Y, Kinoshita M, Toyoshima R. Pharmacological characterization of M1 muscarinic acetylcholine receptormediated Gq activation in rat cerebral cortical and hippocampal membranes. Naunyn Schmiedebergs Arch Pharmacol 2013; 386: 937-947.
141. [141] Bymaster FP, Whitesitt CA, Shannon HE, et al. Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease. Drug Devel Res 1997; 40: 158-170.
142. [142] Shekhar A, Potter WZ, Lightfoot J, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 2008; 165: 1033-1039.
143. [143] Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebocontrolled clinical trial. Arch Gen Psychiatry 2006; 63: 1121-1129.
144. [144] Drevets WC, Furey ML. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry 2010; 67: 432-438.
145. [145] Gillin JC, Sutton L, Ruiz C, et al. The effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group. Biol Psychiatry 1991; 30: 157-169.
146. [146] Voleti B, Navarria A, Liu RJ, et al. Scopolamine rapidly increases Mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry 2013; 74: 742-749.
147. [147] Ehlert FJ, Delen FM, Yun SH, Liem HA. The interaction of amitriptyline, doxepin, imipramine and their N-methyl quaternary ammonium derivatives with subtypes of muscarinic receptors in brain and heart. J Pharmacol Exp Ther 1990; 253: 13-19.
148. [148] Dean B. Evolution of the human CNS cholineric system: has this resulted in the emergence of psychiatric disease? Aust N Z J Psychiatry 2009; 43: 1016-1028.
149. [149] Baumgold J. Effects of verapamil on the binding characteristics of muscarinic receptor subtypes. Eur J Pharmacol 1986; 126: 151-154.
150. [150] Parker G. Modern diagnostic concepts of the affective disorders. Acta Psychiatr Scand Suppl 2003; (418): 24-28.
151. [151] Dean B. Dissecting the Syndrome of Schizophrenia: Progress toward Clinically Useful Biomarkers. Schizophr Res Treatment 2011; 2011: 614730.